Main achievements of the H&M Group in 2022 were as follows:
1) Endocrine and hormone-dependent cancer:
a) Identification of a genetic variant in the CDK8 gene that is associated with sporadic pituitary adenomas in the Portuguese population [doi: 10.3390/ijms231911749];
b) Androgens and low-density lipoprotein-cholesterol interplay in modulating prostate cancer cell fate and metabolism [doi: 10.1016/j.prp.2022.154181];
c) Identification of differences in glycolytic metabolism and oxidative stress markers of cancer cells when exposed to human amniotic membrane proteins [doi: 10.1007/s11033-022-07598-5].
2) Reproductive endocrinology:
a) Volatilomics may be a useful strategy to identify potential biomarkers of female infertility [doi: 10.3390/biomedicines10112852];
b) Identification of pathways whereby diabetes may contribute to male infertility [doi: 10.3390/ijms23168912];
c) Identification of genetic mutations in patients with hypogonadotropic hypogonadism and with disorders of sex development [doi: 10.3390/ijms23084423], [doi: 10.3390/ijms231710026];
d) Iodine supplementation of pregnant women may be insufficient in iodine-deficient regions [doi: 10.3390/nu14071393].
3) Endocrine disruptors: Demonstration of the effect of environmental endocrine disrupting compounds on the cardiovascular system with potential health implications [doi: 10.3390/toxics10090529; doi: 10.1016/j.tox.2022.153158; doi 10.1016/j.chemosphere.2022.135807; doi 10.3390/biomedicines10051054].
Prizes and Awards
Best communication award: Gaspar LM, Gonçalves CI, Saraiva C, Cortez L, Amaral C, Nobre E, Lemos MC. Mutações no gene AIP em doentes portugueses com macroadenomas hipofisários esporádicos de início precoce (Portuguese Congress of Endocrinology, Vilamoura, 2022)